B4GALT5 inhibits CD8<sup>+</sup> T-cell response by downregulating MHC-I level through ERAD pathway in PDAC
B4GALT5 impairs CD8<sup>+</sup> T-cell recognition of tumor cells by regulating MHC-I levels, thereby promoting immune evasion. This makes B4GALT5 a highly promising immunotherapeutic target for improving the poor prognosis of patients with PDAC.
Authors
- Hailong Ma (ORCID: https://orcid.org/0000-0003-4110-1417)
- Xiaqing Li (ORCID: https://orcid.org/0000-0002-7748-7967)
- Shuyu Xiao
- Aziguli Tulamaiti
- Zhigang Zhang (ORCID: https://orcid.org/0000-0001-8965-223X)
- Hui Li (ORCID: https://orcid.org/0000-0001-5339-681X)
- Yuan‐Han Yang (ORCID: https://orcid.org/0000-0002-1918-9021)
- Hao Zhang (ORCID: https://orcid.org/0000-0002-3720-4459)
- Xueli Zhang (ORCID: https://orcid.org/0000-0001-8306-0639)
- Xiao-Mei Yang
- Xin Xing (ORCID: https://orcid.org/0000-0002-4766-4926)
- Yu‐Tong Liu
- Shi-Qi Yin
- Yan-Miao Huo
Institutions
- Shanghai Jiao Tong University (CN)
- Anhui University of Science and Technology (CN)
- Jilin University (CN)
- Renji Hospital (CN)
- Xian Central Hospital (CN)
- Yang Hospital (KR)
- Shanghai Cancer Institute (CN)
- First Hospital of Jilin University (CN)
- Shanghai University of Medicine and Health Sciences (CN)
- Shanghai Sixth People's Hospital (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1136/jitc-2024-010908
- Citations
- 4
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 3.19